Proparacaine 0.5% · ophthalmic solution
Local Anesthetic
Approved uses
Corneal anesthesia of short duration (for example tonometry, gonioscopy, removal of corneal foreign bodies)
1 to 2 drops in each eye as a single instillation before the procedure
Anesthesia is complete within 1 minute and sensitivity returns to baseline by 45 minutes.
Short corneal and conjunctival procedures
1 drop in each eye every 5 to 10 minutes for 5 to 7 doses
Anesthesia starts at 2 minutes, peaks at 15 minutes, and sensitivity is still reduced at 60 minutes.
OFF-LABELNot in the FDA label for this product
Outpatient analgesia for traumatic corneal abrasion
No endorsed regimen, and this entry is not a recommendation. The only randomized trial of take-home proparacaine used a 0.05% dilution; across the trials in the Cochrane review, treatment ran 3 hours to 1 week, most commonly 24 to 48 hours. Neither source states a dosing frequency.
Cochrane · very low certainty
Cochrane review of 9 RCTs and 556 participants: little or no difference from placebo in post-traumatic pain at 24 hours (MD -0.04 on a 10-point scale; 1 RCT, 76 participants) and a 37% higher rate of unresolved epithelial defects (RR 1.37, 95% CI 0.78 to 2.42; 3 RCTs, 221 participants). All outcomes very low certainty, over half the trials at high risk of bias, and the authors do not recommend the practice. The most favorable single trial used dilute 0.05% drops in 33 completers and found better pain reduction than placebo (median VAS improvement 3.9 vs 0.6 cm, P=0.007) with no observed healing delay, but was far too small to detect the complication it is dispensed against.
Contraindications
Known hypersensitivity to any ingredient of the preparation.
Proparacaine HCl 0.5% (5 mg/mL) ophthalmic solution, 15 mL dropper bottle
Rapidly acting topical local anesthetic (a benzoic acid ester) with induced anesthesia lasting approximately 10 to 20 minutes. Proparacaine is used to inhibit voltage-gated sodium channels on neuronal membranes to prevent signal propagation and pain signaling. A physiology text states that most local anesthetics act directly on the activation gates of the sodium channels, making it much more difficult for these gates to open and thereby reducing membrane excitability (it names procaine and tetracaine, not proparacaine).
Warnings & Precautions
- Not for injection: For topical ophthalmic use only.
- Corneal opacification: Prolonged use is not recommended; it may produce permanent corneal opacification with accompanying visual loss.
- Direct supervision: Indicated for administration under the direct supervision of a healthcare provider and not intended for patient self-administration.
- Anesthetic abuse keratopathy: Abuse of topical anesthetics can produce a nonhealing epithelial defect with a stromal ring infiltrate. In a three-patient case series, all three needed a conjunctival flap and two a penetrating keratoplasty; in a four-case report, all four were originally diagnosed as Acanthamoeba keratitis. In a retrospective review of 19 patients, ring-shaped keratitis appeared in 57.7% of eyes, hypopyon in 42.3%, and the mean epithelization period was 19.96 days.
- Outpatient dispensing: A Cochrane review of nine parallel-group randomized trials with a total of 556 participants found little or no certainty about efficacy for reducing ocular pain in the initial 24 to 72 hours after a corneal abrasion and no evidence of a substantial effect on epithelial healing up to 72 hours; the authors had very low confidence in this evidence as a basis to recommend topical anesthetics.
- Solution appearance: Should be clear to straw-color; discard if it becomes darker.
- Storage: Refrigerate at 2 to 8 degrees C and keep the bottle in its unit carton to protect from light.
Common Side Effects
Occasional temporary stinging, burning, and conjunctival redness may occur. Corneal edema has been reported following use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction has been reported, with acute, intense, and diffuse epithelial keratitis, a gray ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments, and sometimes iritis with descemetitis. Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.
Pregnancy: No animal reproduction studies have been conducted, and it is unknown whether the drug can cause fetal harm or affect reproductive capacity; administer only if clearly needed.
Lactation: It is not known whether this drug is excreted in human milk, so caution should be exercised when it is administered to a nursing woman.
Established in pediatric patients, supported by controlled studies in adults and children over age 12 plus safety data in neonates and other pediatric patients.